Immunotherapies have revolutionized the treatment paradigms of various types of cancers.
However, most of these immunomodulatory strategies focus on harnessing adaptive …

Myeloid-derived suppressor cells (MDSCs) are a heterogenic population of immature
myeloid cells with immunosuppressive effects, which undergo massive expansion during …

Immunotherapies like the adoptive transfer of gene-engineered T cells and immune
checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some …

Cancer immunotherapy has received extensive attention due to its ability to activate the
innate or adaptive immune systems of patients to combat tumors. Despite a few clinical …

Breast cancer (BC) is the most common malignant tumor among women, with high morbidity
and mortality. Its onset, development, metastasis, and prognosis vary among individuals due …

Chimeric antigen receptor modified T cells (CAR-T) therapy is an emerging immunotherapy
against malignancies. However, only limited success was obtained in solid tumors …

Background Immune checkpoint blockade (ICB) targeting programmed cell death protein 1
and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as …

Myeloid-derived suppressor cells (MDSCs) are a population of immature myeloid cells
defined by their immunosuppression. Elevated levels of certain soluble cytokines in tumor …

Myeloid cells are critically involved in the pathophysiology of cancers. In the tumor
microenvironment (TME), they comprise tumor-associated macrophages (TAMs), neutrophils …

Myeloid-derived suppressor cells (MDSCs) play a critical role in maintaining the tumor
immune microenvironment; thus, the promotion of MDSC polarization will improve …